Why the study?
Previous animal studies suggest that THC attenuates intestinal inflammation, but its effects on doxorubicin-induced gastrointestinal mucositis and DSS-induced colitis remained to be investigated.
Does THC reduce gastrointestinal toxicity in doxorubicin-induced mucositis and DSS-induced colitis in mice?
Does THC reduce gastrointestinal toxicity in doxorubicin-induced mucositis and DSS-induced colitis in mice?
Answers are grounded in this paper and cite their sources.
THC alleviates doxorubicin-induced weight loss and intestinal shortening in mice but does not affect intestinal inflammation or DSS-induced colitis.
BACKGROUND: Gastrointestinal mucositis is a common adverse effect of chemotherapy. Inflammatory bowel diseases (IBD) are a spectrum of chronic inflammatory disorders of the digestive tract. Mucositis and IBD/colitis are characterized by weight loss and intestinal inflammation. Previous animal studies suggest that the cannabinoid, ∆9-tetrahydrocannabinol (THC), attenuates intestinal inflammation. We aimed to investigate the effect of THC oil on doxorubicin-induced gastrointestinal mucositis and dextran sodium sulphate (DSS) induced colitis in mice. METHODS: Wild-type C57BL6 mice were used for the experiments. The mice received a daily dose of THC oil at either 10 mg/kg or 20 mg/kg or vehicle by oral gavage. Mucositis was induced by intraperitoneal injection of doxorubicin, while colitis was induced by supplementing the drinking water with 2% DSS. Gastrointestinal toxicity was evaluated by weight, intestinal lengths, histopathological evaluation, and expression of genes related to chemotherapy-induced mucositis and intestinal inflammation. RESULTS: Treatment with THC significantly reduced weight loss and increased the length of the small intestine in the doxorubicin-treated mice. No effects on gene expression of pro-inflammatory cytokines were observed. No effect of THC was observed in DSS-induced colitis. CONCLUSIONS: THC reduced doxorubicin-induced weight loss, possibly due to increased appetite, but did not affect doxorubicin-induced intestinal inflammation or DSS-induced colitis in mice.
No takes yet. Share an insight, caveat, or question.
Johansen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: